Raymond James Financial Services Advisors
ALXN

Raymond James Financial Services Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-35,079
Closed -$6.44M – 3458
2021
Q2 		$6.44M Buy
35,079
+3,820
+12% +$656K 0.01% 860
2021
Q1 		$4.78M Sell
31,259
-8,861
-22% -$1.37M 0.01% 927
2020
Q4 		$6.27M Sell
40,120
-10,372
-21% -$1.33M 0.02% 741
2020
Q3 		$5.78M Buy
50,492
+18,439
+58% +$1.99M 0.02% 698
2020
Q2 		$3.6M Sell
32,053
-2,466
-7% -$262K 0.01% 840
2020
Q1 		$3.1M Buy
34,519
+10,320
+43% +$1.01M 0.01% 697
2019
Q4 		$2.62M Buy
24,199
+1,568
+7% +$168K 0.01% 1040
2019
Q3 		$2.22M Buy
22,631
+2,297
+11% +$259K 0.01% 1049
2019
Q2 		$2.66M Buy
20,334
+279
+1% +$36K 0.01% 947
2019
Q1 		$2.71M Sell
20,055
-2,243
-10% -$279K 0.01% 921
2018
Q4 		$2.17M Buy
22,298
+548
+3% +$64.8K 0.01% 860
2018
Q3 		$3.02M Sell
21,750
-5,726
-21% -$718K 0.01% 859
2018
Q2 		$3.41M Buy
27,476
+1,464
+6% +$171K 0.02% 762
2018
Q1 		$2.9M Sell
26,012
-1,423
-5% -$170K 0.02% 779
2017
Q4 		$3.28M Sell
27,435
-3,109
-10% -$379K 0.02% 706
2017
Q3 		$4.29M Sell
30,544
-4,238
-12% -$576K 0.03% 582
2017
Q2 		$4.23M Buy
34,782
+2,871
+9% +$334K 0.03% 566
2017
Q1 		$3.87M Sell
31,911
-20,522
-39% -$2.65M 0.03% 573
2016
Q4 		$6.42M Sell
52,433
-99,772
-66% -$12.2M 0.05% 374
2016
Q3 		$18.7M Sell
152,205
-478
-0.3% -$61.5K 0.17% 146
2016
Q2 		$17.8M Buy
152,683
+4,775
+3% +$677K 0.17% 146
2016
Q1 		$20.6M Buy
147,908
+30,907
+26% +$4.54M 0.24% 97
2015
Q4 		$22.3M Buy
+117,001
New +$20.4M 0.26% 90

Other funds holding ALXN

Brinker Capital Investments
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TD Ameritrade Investment Management
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Raymond James Financial Services Advisors's ALXN Position: Q3 2021 in Review

Raymond James Financial Services Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 35,079 shares — an estimated $6.44M sold.

Raymond James Financial Services Advisors first reported a position in ALXN in Q4 2015 and held it in 23 quarters. The position peaked at $22.3M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Raymond James Financial Services Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 35,079 Alexion Pharmaceuticals shares in Q3 2021, an estimated $6.44M.
  • Raymond James Financial Services Advisors first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 23 quarters.
  • Raymond James Financial Services Advisors's Alexion Pharmaceuticals position peaked at $22.3M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.